Investors flock to psychiatric treatments after FDA approves new schizophrenia drug
December 23, 2019 at 14:42 PM EST
The approval of Intra-Cellular Therapies Inc.’s schizophrenia drug Caplyta on Monday is the latest indicator that some drug developers are finally prioritizing psychiatric treatments despite the challenges of bringing them to market.